Effects of Subantimicrobial-Dose Doxycycline in the Treatment of Moderate Acne

Abstract

Objective: To determine if treatment with subantimicrobial-dose (SD) doxycycline hyclate (20-mg tablets taken twice daily) improved clinical outcome, had any detectable effect on skin flora, led to overgrowth or colonization of skin by opportunistic pathogens, or resulted in an increase in antibiotic resistance by the surface skin microflora in patients with moderate acne compared with placebo.

Subantimicrobial‐Dose Doxycycline Modulates Gingival Crevicular Fluid Biomarkers of Periodontitis in Postmenopausal Osteopenic Women

“…However, significantly fewer SDD subjects experienced a dermatologic AE, such as rash, acne, rosacea, and hives, during the clinical trial (2% for the SDD group versus 17% for the placebo group; P = 0.002). These data are consistent with previous studies showing evidence of the safety and efficacy of SDD in adults with the inflammatory skin diseases acne and rosacea 37–39 and in subjects with the inflammatory joint disease, rheumatoid arthritis 40 …”

Modified‐Release Subantimicrobial Dose Doxycycline Enhances Scaling and Root Planing in Subjects With Periodontal Disease

“…The results of the microbiologic analyses are in agreement with previously published findings 6‐8,23,31 concerning 20‐mg, twice‐daily formulations of SDD. They demonstrate that long‐term use of SDD‐40 does not result in a change in the microbial flora, an increase in the proportion of the flora resistance to 4 μg/ml doxycycline, an increase or overgrowth by periodontal or opportunistic pathogens, an increase in resistance to doxycycline by any individual bacterial species, the acquisition of doxycycline resistance by bacteria previously susceptible, or the emergence of cross‐resistance or multiantibiotic resistance.…”

“…The data suggest that compliance was improved with the once‐daily formulation of SDD‐40 compared to previous studies of 20‐mg doses, although this needs to be confirmed in future studies. Again, similar to studies 6–8 of 20‐mg doses of SDD, there was no evidence of any long‐term treatment effect of SDD‐40 on the microbial flora, including any development of antibiotic resistance. The data from this study confirm that SDD‐40 is a safe and effective therapy and support its use as an adjunct to SRP in the management of subjects with periodontitis.…”

Subantimicrobial dose doxycycline effects on alveolar bone loss in post‐menopausal women

“…This clinical trial demonstrated the safety of SDD over a 2-year period when compared with placebo, as adverse events among SDD subjects were similar to placebo. However, significantly fewer SDD subjects experienced a dermatologic adverse event than placebo subjects, which is in agreement with the recent literature that demonstrates the effectiveness of SDD in the treatment of acne and rosacea (Skidmore et al 2003, Sanchez et al 2005). In addition, this is the longest-duration clinical trial that has examined the safety and efficacy of SDD.…”